These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12954176)

  • 41. Asymmetric membrane in membrane capsules: a means for achieving delayed and osmotic flow of cefadroxil.
    Philip AK; Pathak K; Shakya P
    Eur J Pharm Biopharm; 2008 Jun; 69(2):658-66. PubMed ID: 18206358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase transited and vapor-induced dual capsular system (DCS) for achieving delayed and osmotic release of cefadroxil.
    Philip AK; Philip B
    Pharm Dev Technol; 2011 Oct; 16(5):457-65. PubMed ID: 20482448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and evaluation of oral osmotic pump of butorphanol tartrate.
    Shah B; Raichandani Y; Misra A
    Pharm Dev Technol; 2014 Nov; 19(7):868-80. PubMed ID: 24079361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
    Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
    Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Production and
    Ma C; Huang Z; Zhu Y; Chen X; Singh V; Huang Y; Pan X; Wu C
    Pharmazie; 2017 Sep; 72(9):511-517. PubMed ID: 29441977
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
    Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
    Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.
    Kim YH; Choi KS; Kam SH; Lee KH; Park JS
    Arzneimittelforschung; 2012 Dec; 62(12):576-82. PubMed ID: 23093481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system.
    Kumaravelrajan R; Narayanan N; Suba V; Bhaskar K
    Int J Pharm; 2010 Oct; 399(1-2):60-70. PubMed ID: 20696225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility.
    Philip AK; Pathak K
    AAPS PharmSciTech; 2006 Jul; 7(3):56. PubMed ID: 17025237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlled-release isosorbide dinitrate pellets. Part I: Design and evaluation of controlled-release capsule dosage form.
    Lalla JK; Bhat SU
    J Pharm Sci; 1993 Dec; 82(12):1288-91. PubMed ID: 8308715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel application of electrospinning technique in sublingual membrane: characterization, permeation and in vivo study.
    Chen J; Wang X; Zhang W; Yu S; Fan J; Cheng B; Yang X; Pan W
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1365-74. PubMed ID: 26716771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Release characteristics and in vitro-in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling.
    Lin HL; Lin SY; Lin YK; Ho HO; Lo YW; Sheu MT
    Eur J Pharm Biopharm; 2008 Sep; 70(1):289-301. PubMed ID: 18539015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia.
    Hennig L; Andresen D; Hennig A; Levenson B; Brüggemann T; Schröder R
    J Clin Pharmacol; 1991 Jul; 31(7):636-40. PubMed ID: 1894759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Push-pull osmotic pump for zero order delivery of lithium carbonate: development and in vitro characterization.
    Patel V; Chudasama A; Nivsarkar M; Vasu K; Shishoo C
    Pharm Dev Technol; 2012; 17(3):375-82. PubMed ID: 21284541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.